Pfizer Inc. Chief Executive Albert Bourla said the company secured a three-year grace period from President Trump’s promised tariffs on pharmaceuticals in a deal that would lower some of the company’s ...
Madrigal has paid Pfizer $50 million for the rights to a DGAT2i inhibitor with the intention of combining the drug with its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback